• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content

Medxy AI

  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance
Posted inClinical Updates Wellness & Lifestyle

Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance

Posted by By MedXY 08/03/2025
New GRADE sub-study reveals that somatic symptoms of depression, not cognitive-affective symptoms, are chiefly associated with inflammation and insulin resistance in type 2 diabetes, highlighting a pathophysiological bridge for targeted interventions.
Read More
Seasonal Malaria Chemoprevention in Uganda: Efficacy of SPAQ and Dihydroartemisinin-Piperaquine in the Era of Drug Resistance
Posted inClinical Updates Wellness & Lifestyle

Seasonal Malaria Chemoprevention in Uganda: Efficacy of SPAQ and Dihydroartemisinin-Piperaquine in the Era of Drug Resistance

Posted by By MedXY 08/03/2025
A large cluster-randomised trial in Uganda demonstrates that both SPAQ and dihydroartemisinin-piperaquine are highly effective and safe for seasonal malaria chemoprevention in children, with no evidence of resistance selection.
Read More
Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial
Posted inClinical Updates Wellness & Lifestyle

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

Posted by By MedXY 08/03/2025
The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.
Read More
Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?
Posted inClinical Updates Wellness & Lifestyle

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

Posted by By MedXY 08/03/2025
Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.
Read More
Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial
Posted inClinical Updates Wellness & Lifestyle

Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial

Posted by By MedXY 08/03/2025
The DISTRICTS trial demonstrates that initial surgical treatment for carpal tunnel syndrome leads to significantly higher recovery rates at 18 months compared to starting with corticosteroid injections, despite similar adverse event profiles.
Read More
Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?
Posted inClinical Updates Wellness & Lifestyle

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

Posted by By MedXY 08/03/2025
Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.
Read More
First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial
Posted inClinical Updates Wellness & Lifestyle

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

Posted by By MedXY 08/03/2025
The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic toxicity.
Read More
Online Video Versus Face-to-Face Preoperative Consultation for Major Abdominal Surgery: Insights from the VIDEOGO Non-Inferiority Trial
Posted inClinical Updates Wellness & Lifestyle

Online Video Versus Face-to-Face Preoperative Consultation for Major Abdominal Surgery: Insights from the VIDEOGO Non-Inferiority Trial

Posted by By MedXY 08/03/2025
The VIDEOGO trial shows that online video consultations are non-inferior to face-to-face consultations for preoperative assessment in major abdominal surgery, achieving similar patient satisfaction and information recall.
Read More
Targeted Pneumococcal Vaccination in New Older Adult Care Home Residents: Evidence from National Surveillance in England
Posted inClinical Updates Wellness & Lifestyle

Targeted Pneumococcal Vaccination in New Older Adult Care Home Residents: Evidence from National Surveillance in England

Posted by By MedXY 08/03/2025
Vaccinating new older adult care home residents with PCV20 or PPV23 could prevent substantially more invasive pneumococcal disease cases and deaths per dose than standard age-based vaccination, supporting policy revision.
Read More
Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts
Posted inClinical Updates

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

Posted by By MedXY 08/03/2025
MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.
Read More
Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial
Posted inClinical Updates Wellness & Lifestyle

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

Posted by By MedXY 08/03/2025
A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.
Read More
Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial
Posted inClinical Updates Wellness & Lifestyle

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

Posted by By MedXY 08/03/2025
The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.
Read More
Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial
Posted inClinical Updates Wellness & Lifestyle

Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial

Posted by By MedXY 08/03/2025
The IMPORT LOW trial confirms that partial-breast and reduced-dose radiotherapy are as effective and safe as whole-breast radiotherapy for selected women with early breast cancer, supporting their use as standard care.
Read More
Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia
Posted inClinical Updates Wellness & Lifestyle

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

Posted by By MedXY 08/03/2025
Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.
Read More
Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Posted inClinical Updates Wellness & Lifestyle

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

Posted by By MedXY 08/03/2025
Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.
Read More
Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial
Posted inClinical Updates Wellness & Lifestyle

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

Posted by By MedXY 08/03/2025
The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.
Read More
Zanidatamab Plus Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastro-Oesophageal Adenocarcinoma: Clinical Efficacy and Safety Insights from a Phase 2 Study
Posted inClinical Updates Wellness & Lifestyle

Zanidatamab Plus Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastro-Oesophageal Adenocarcinoma: Clinical Efficacy and Safety Insights from a Phase 2 Study

Posted by By MedXY 08/03/2025
Zanidatamab combined with chemotherapy shows promising efficacy and manageable safety in first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma, with durable responses and improved survival outcomes.
Read More
Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results
Posted inClinical Updates Wellness & Lifestyle

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

Posted by By MedXY 08/02/2025
The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.
Read More
Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland
Posted inClinical Updates Wellness & Lifestyle

Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland

Posted by By MedXY 08/02/2025
The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.
Read More
Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial
Posted inClinical Updates Wellness & Lifestyle

Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial

Posted by By MedXY 08/02/2025
The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.
Read More

Posts pagination

Previous page 1 … 61 62 63 64 65 … 80 Next page
  • Immunogenicity and Safety of the VLA15 Lyme Borreliosis Vaccine Across Age Groups: A Phase 2 Randomised Controlled Trial and Integrative Review
  • MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management
  • Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial
  • Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
  • Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence
Post You Might Like
Posted inClinical Updates Wellness & Lifestyle
Immunogenicity and Safety of the VLA15 Lyme Borreliosis Vaccine Across Age Groups: A Phase 2 Randomised Controlled Trial and Integrative Review
Posted by By MedXY 09/21/2025
Posted inClinical Updates Wellness & Lifestyle
MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management
Posted by By MedXY 09/21/2025
Posted inClinical Updates Wellness & Lifestyle
Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial
Posted by By MedXY 09/21/2025
Posted inClinical Updates Wellness & Lifestyle
Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
Posted by By MedXY 09/21/2025
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging AI artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COPD COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity MASH mental health metformin Mortality nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch thử nghiệm lâm sàng tirzepatide type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top